Clinical trials: Chronic Myelogenous Leukaemia
Chronic Phase CML
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy
This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
- Trial name
- NCT01490775
- Testing
- no access to eMedonline, eMedonline access
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rex Cancer Center, Raleigh, NC
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells and prepares the…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00376519
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase…
- Trial name
- NCT00428077
- Testing
- bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Gene Expression Profiles in CML Non-responders
Gene Expression Profiles in CML Non-responders
Chronic myeloid leukaemia (CML) is a haematological malignancy primarily driven by the fusion oncogene BCR-ABL1, resulting in a constitutively expressed tyrosine kinase.
- Trial name
- NCT04219111
- Testing
- Clariom
- Where
- United Kingdom
- Sponsor
- Sheffield Children's NHS Foundation Trust
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
T-cell Depleted Alternative Donor Transplantation
The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00968864
- Testing
- CliniMACS® (T cell depletion)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Myelogenous Leukemia, BCR/ABL Positive
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
This protocol is a multicentric interventional phase II study from the French CML Intergroup (FILMC). The core of the protocol is to explore the efficacy and safety of an optimization strategy consisting in the modulation of the…
- Trial name
- OPTIM-DASA (NCT01916785)
- Testing
- Dasatinib
- Where
- 34 sites in Canada, France
- Volunteers
- 289 people
- Sponsor
- Versailles Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor peripheral stem cell transplantation may reduce the chance of developing graft-versus-host disease following transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00054340
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myelomonocytic Leukemia, Chronic
Cohort of Patients With Chronic Myelomonocytic Leukemia
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or…
- Trial name
- MYELOMONO-3 (NCT07512882)
- Testing
- Sampling
- Where
- 24 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Myeloproliferative Disorders, Polycythemia Vera
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
This study involves observing the level of cell cycle regulatory gene in patients with myeloproliferative disorders(MPD). These disorders include polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF) and…
- Conditions
- Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT02663648
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Shandong University
Chronic Myelogenous Leukemia
Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention
The purpose of this study is to evaluate Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) with fatigued chronic myelogenous leukemia (CML) patients on tyrosine kinase inhibitors (TKIs) for feasibility…
- Trial name
- NCT02592447
- Testing
- Therapy for Targeted Therapy-related Fatigue (TTF), Wait-List Control Condition (WLC)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myeloid Leukemia, Chronic
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase…
- Trial name
- DASISION (NCT00481247)
- Testing
- Dasatinib, Imatinib
- Where
- 109 sites in United States, Argentina and 25 more
- Volunteers
- 547 people
- Sponsor
- Bristol-Myers Squibb
Acute Leukemias, Chronic Leukemias
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age.
- Conditions
- Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01339988
- Testing
- Busulfan/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or non-small cell lung cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00039091
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
MDS, AML, Adult
Quality of Life-Guided Transfusion in Refractory MDS or AML
Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of…
- Conditions
- MDS, AML, Adult, Anemia
- Trial name
- Q-TRANS (NCT07328191)
- Testing
- Red blood cell transfusions based on EQ-5D-5L questionnaire
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Chronic Myeloid Leukemia (CML)
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
Imatinib is a tyrosine kinase inhibitor that has improved the prognosis of patients with chronic myeloid leukemia (CML). CML has become a chronic disease requiring long-term administration of imatinib.
- Trial name
- K2SPIRIT (NCT06646978)
- Testing
- Imatinib (STI571)
- Where
- France
- Volunteers
- 787 people
- Sponsor
- Poitiers University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.